Harsco signs agreement to acquire Clean Earth for $625 million
Category: #business  By Nikita Chaurasia  Date: 2019-05-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Harsco signs agreement to acquire Clean Earth for $625 million

The acquisition of Clean Earth is expected accretive to earnings in 2020. The companies together are expecting synergies to amount to $10 million by 2020.

Harsco Corporation, the industrial services provider recently announced that it has entered into a definitive agreement for the acquisition of Clean Earth, a leading waste management company in the U.S. The deal was closed for cash transaction of $625 million.

For the record, Clean Earth leads the hazardous waste market and is the largest operator in dredged and contaminated material management market. Operating over 27 permitted facilities in the U.S., the company maintains a portfolio of 200 rare and hard to replicate permits, with a cent percent permit renewal success rate. In 2019, it is expected to generate a revenue of approximately $300 million and $65 million of adjusted EBITDA, cites source. In unison with Clean Earth, Harsco plans to expand its portfolio with a wide range of customized environmental solutions and services.

The Chairman and CEO of Harsco, Nick Grasberger reportedly said that the acquisition is expected to benefit Harsco’s customers and shareholders such as higher profit margins, cost savings, recurring revenues, and potential cross-selling opportunities. Crediting Clean Earth, he further added the strong track-record of growth, safety performance, talented employees and management team is a valuable addition for Harsco.

Grasberger also said that Harsco has been working toward a strategic transformation of its portfolio to create more value for shareholders. The addition of ALTEK Group in May 2018 and the recent acquisition of Clean Earth besides the exit of certain businesses are expected to take Harsco closer to its goal of becoming a global environmental solutions market leader.

Reportedly, Harsco’s strategy will gain hold of large-scale capabilities in the contaminated materials, hazardous waste and dredge material markets, which are complementary to its Metals and Mineral environmental solutions and services offerings.

The acquisition of Clean Earth is expected accretive to earnings in 2020. The companies together are expecting synergies to amount to $10 million by 2020.

 

Source Credit: https://www.globenewswire.com/news-release/2019/05/09/1820551/0/en/Harsco-Enters-Into-Definitive-Agreement-to-Acquire-Clean-Earth-Accelerating-its-Transformation-to-a-Global-Market-Leader-of-Environmental-Solutions.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...

Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
By Nikita Chaurasia

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showcased during the ACC.20/WCC. In a...